Exclusive: Clovis Oncology Inc Can’t Be More Safe. Trades Significantly Higher

Exclusive: Clovis Oncology Inc Can't Be More Safe. Trades Significantly Higher

The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! About 2.25 million shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 75.84% since February 26, 2016 and is uptrending. It has outperformed by 65.41% the S&P500.
The move comes after 5 months positive chart setup for the $1.32B company. It was reported on Oct, 1 by Barchart.com. We have $50.04 PT which if reached, will make NASDAQ:CLVS worth $514.80 million more.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 EPS, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.

Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage

Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. As per Tuesday, November 17, the company rating was downgraded by WallachBeth Capital. The company was maintained on Wednesday, August 24 by Suntrust Robinson. The company was reinitiated on Monday, April 4 by Piper Jaffray. The firm has “Buy” rating given on Friday, September 23 by Suntrust Robinson. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Buy” rating by SunTrust on Friday, September 23. The firm has “Hold” rating given on Monday, May 9 by WallachBeth Capital. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Buy” rating by SunTrust on Wednesday, August 24. The firm has “Neutral” rating given on Wednesday, August 24 by Mizuho. On Friday, August 5 the stock rating was initiated by Suntrust Robinson with “Buy”.

According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.13, from 0.87 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Moreover, Blackrock Fund Advsrs has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 1.27M shares. Tiaa Cref Invest Limited Liability Com has 0% invested in the company for 126,493 shares. State Board Of Administration Of Florida Retirement holds 0% or 22,819 shares in its portfolio. The Germany-based Deutsche Fincl Bank Ag has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Partner Investment Mgmt L P owns 31,406 shares or 0.71% of their US portfolio. Meeder Asset holds 0.01% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 6,132 shares. Manufacturers Life Ins Communications The accumulated 22,698 shares or 0% of the stock. New York State Common Retirement Fund has 39,782 shares for 0% of their US portfolio. Proshare Advsr Limited Company holds 0.01% or 33,584 shares in its portfolio. Nelson Van Denburg & Campbell Wealth Gp Lc has invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Moreover, Citigroup has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 942 shares. Samlyn Cap Ltd Liability Corporation holds 678,410 shares or 0.22% of its portfolio. Credit Suisse Ag, a Switzerland-based fund reported 122,697 shares. Quantitative Systematic Strategies Ltd Liability reported 49,852 shares or 0.35% of all its holdings. The California-based California State Teachers Retirement Systems has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS).

More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Fool.com which released: “Why Clovis Oncology Inc. Is Soaring Today” on September 08, 2016, also Fool.com with their article: “Is Clovis Oncology Still a Strong Buy?” published on September 12, 2016, Businesswire.com published: “Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress” on September 28, 2016. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Benzinga.com and their article: “Clovis Upgraded At Credit Suisse Following Acquisition Rumor” published on September 21, 2016 as well as Fool.com‘s news article titled: “Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags …” with publication date: September 01, 2016.

CLVS Company Profile

Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment